SCHEMBL3249493

SCHEMBL3249493

COc1ccc(S(=O)(=O)NCC(=O)Nc2ccc(Cl)cc2Cc2c(Cl)cccc2Cl)cc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.51
TSHR P16473 2/20 0.49
KMT2A Q03164 2/20 0.48
F2 P00734 2/20 0.47
TMPRSS6 Q8IU80 1/20 0.47
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
ALDH1A1 P00352 4/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
PKM P14618 1/20 0.45
CYP2C19 P33261 1/20 0.45
MAPT P10636 2/20 0.44
OXTR P30559 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
MEP1B Q16820 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3256933 0.96 MAPK1 (0.49) MAPK1TSHRKMT2AF2TMPRSS6
SCHEMBL4863941 0.94 ALDH1A1 (0.48) MAPK1TSHRKMT2AF2TMPRSS6
SCHEMBL3256517 0.91 ALDH1A1 (0.51) MAPK1TSHRKMT2AF2TMPRSS6
SCHEMBL3247755 0.91 MAPK1 (0.59) MAPK1TSHRKMT2AF2TMPRSS6
SCHEMBL3247461 0.90 FLT1 (0.52) MAPK1TSHRKMT2AF2TMPRSS6
SCHEMBL4867720 0.89 ALDH1A1 (0.49) MAPK1TSHRKMT2AF2TMPRSS6
SCHEMBL3250145 0.89 KMT2A (0.48) MAPK1TSHRKMT2AF2TMPRSS6
SCHEMBL3247471 0.88 TSHR (0.52) MAPK1TSHRKMT2AF2TMPRSS6
SCHEMBL3250762 0.88 MAPT (0.53) MAPK1TSHRKMT2AF2TMPRSS6
SCHEMBL3255406 0.87 MEP1B (0.51) MAPK1TSHRKMT2AF2TMPRSS6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 MAPK1 2674/4885TSHR 29/4885KMT2A 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.